Pàgina inicial > Resultats de la cerca: Macé, Sandrine
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
9 p, 1.5 MB Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma : updated results from IKEMA, a randomized Phase 3 study / Martin, Thomas (University of California at San Francisco, USA) ; Dimopoulos, Meletios (University of Athens, Greece) ; Mikhael, Joseph (Translational Genomics Research Institute. City of Hope Cancer Center, Phoenix, USA) ; Yong, Kwee (University College Hospital, London, UK) ; Capra, Marcelo (Centro Integrado de Hematologia e Oncologia. Hospital Mãe de Deus, Porto Alegre, Brazil) ; Facon, Thierry (Lille University Hospital, France) ; Hajek, Roman (University of Ostrava, Czech Republic) ; Špička, Ivan (Department of Hematology. 1st Faculty of Medicine. Charles University and General Hospital, Prague, Czech Republic) ; Baker, Ross (Murdoch University, Perth, Australia) ; Kim, Kihyun (Sungkyunkwan University School of Medicine, Seoul, South Korea) ; Martinez, Gracia (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil) ; Min, Chang-Ki (The Catholic University of Korea) ; Pour, Ludek (University Hospital Brno (República Txeca)) ; Leleu, Xavier (Service d'Hématologie et Thérapie Cellulaire. CHU and CIC Inserm, France) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital, Seoul, South Korea) ; Suzuki, Kenshi (Japanese Red Cross Medical Center, Tokyo, Japan) ; Casca, France (Ividata Life Science, Levallois-Perret, France) ; Macé, Sandrine (Sanofi, R&D, Chilly-Mazarin, France) ; Risse, Marie-Laure (Sanofi, R&D, Vitry-sur-Seine, France) ; Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety. [...]
2023 - 10.1038/s41408-023-00797-8
Blood Cancer Journal, Vol. 13 Núm. 1 (december 2023)  
Registre complet - Creative Commons
2.
9 p, 982.6 KB Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics : IKEMA subgroup analysis / Spicka, Ivan (Charles University and General Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Facon, Thierry (Lille University Hospital) ; Martínez, Gracia (Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital) ; Lim, Andrew (Austin and Repatriation Medical Center) ; Mikala, Gabor (South Pest Central Hospital) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Yağci, Münci (Gazi University) ; Cavo, Michele (Università di Bologna) ; Risse, Marie-Laure (Sanofi (França)) ; Asset, Gaëlle (Sanofi (França)) ; Macé, Sandrine (Sanofi (França)) ; Van de Velde, Helgi (Sanofi) ; Yong, Kwee (University College Hospital) ; Universitat Autònoma de Barcelona
Introduction: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. [...]
2022 - 10.1111/ejh.13835
European Journal of Haematology, Vol. 109 Núm. 5 (november 2022) , p. 504-512  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem